Trial · NCT07910110
Neurobiological Markers of Non-suicidal Self-injury and Treatment Mechanisms of Adolescent Self-injury Intervention Skills Training
NCT07910110, Not applicable, Recruiting, Seoul National University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Neurobiological Markers of Non-suicidal Self-injury and Treatment Mechanisms of Adolescent Self-injury Intervention Skills Training. Trials, record NCT07910110. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07910110
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Neurobiological Markers of Non-suicidal Self-injury and Treatment Mechanisms of Adolescent Self-injury Intervention Skills Training
- NCT number
- NCT07910110
- Status
- Recruiting
- Phases
- Not applicable
- Enrollment
- 100 participants, estimated
- Lead sponsor
- Seoul National University
- Conditions
- Non-suicidal Self-injury (NSSI), Adolescent
- Interventions
- Adolescent Self-Injury Intervention Skills Training (ASIST), Treatment as Usual (TAU)
- First posted
- 2026-11-02
- Last updated
- 2026-11-02
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Self-Harming Behaviors as Assessed by the Self-Harm Inventory (SHI) | Baseline (V1, Week 1), Post-intervention (V5, Weeks 4-5), and 4-week Follow-up (V6, Weeks 8-9) | Self-harming behaviors will be assessed using the Korean version of the Self-Harm Inventory (SHI), a 20-item self-report questionnaire evaluating the frequency of self-harming and self-destructive behaviors. Participants rate each item based on their experiences over the past 4 weeks or their current experiences, using a 4-point Likert scale ranging from 1 (almost never) to 4 (always). Total scores range from 20 to 80, with higher scores indicating more frequent or severe self-harming behaviors. Changes in total SHI scores will be evaluated from baseline (V1) to post-intervention (V5) and from baseline (V1) to the 4-week follow-up (V6). |
| Secondary | Change in Frequency of Non-Suicidal Self-Injury as Assessed by the Korean Inventory of Statements About Self-Injury (K-ISAS) | Baseline (V1, Week 1), Post-intervention (V5, Weeks 4-5), and 4-week Follow-up (V6, Weeks 8-9) | The functions of non-suicidal self-injury (NSSI) will be assessed using the K-ISAS, a self-report questionnaire evaluating NSSI behaviors and their underlying functions. The assessment of NSSI functions consists of 39 items measuring 13 functions of NSSI, categorized into intrapersonal and interpersonal functions. Each item is rated on a 3-point Likert scale ranging from 0 (not relevant) to 2 (very relevant), yielding a total score ranging from 0 to 78. Higher scores indicate greater endorsement of NSSI functions. Changes in total scores will be evaluated from baseline (V1) to post-intervention (V5) and from baseline (V1) to the 4-week follow-up (V6). |
| Secondary | Change in Severity of Suicidal Ideation as Assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS) | Baseline (V1, Week 1), Post-intervention (V5, Weeks 4-5), and 4-week Follow-up (V6, Weeks 8-9) | Suicidal ideation severity will be assessed using the C-SSRS, assessing suicidal ideation and behavior. Suicidal ideation severity is evaluated using five yes/no items and scored on a scale from 0 (no suicidal ideation) to 5 (active suicidal ideation with a specific plan and intent). Higher scores indicate greater severity of suicidal ideation. A suicidal ideation severity score of 4 or higher will be used as the cutoff for elevated suicide risk in this study. Changes in suicidal ideation severity scores will be evaluated from baseline (V1) to post-intervention (V5) and from baseline (V1) to the 4-week follow-up (V6). |
| Secondary | Change in Emotion Regulation Difficulties as Assessed by the Difficulties in Emotion Regulation Scale-16 (DERS-16) | Baseline (V1, Week 1), Post-intervention (V5, Weeks 4-5), and 4-week Follow-up (V6, Weeks 8-9) | DERS-16 is a 16-item self-report questionnaire designed to assess difficulties in emotion regulation across five domains: nonacceptance of emotional responses, difficulties engaging in goal-directed behavior, impulse control difficulties, limited access to emotion regulation strategies, and lack of emotional clarity. Each item is rated on a 5-point Likert scale ranging from 0 (almost never) to 5 (almost always), yielding a total score ranging from 16 to 80. Higher scores indicate greater difficulties in emotion regulation. Changes in total DERS-16 scores will be evaluated from baseline (V1) to post-intervention (V5) and from baseline (V1) to the 4-week follow-up (V6). |
| Secondary | Change in Impulsivity as Assessed by the Barratt Impulsiveness Scale-Brief (BIS-Brief) | Baseline (V1, Week 1), Post-intervention (V5, Weeks 4-5), and 4-week Follow-up (V6, Weeks 8-9) | The BIS-Brief is an 8-item self-report questionnaire designed to assess impulsivity as a unidimensional construct. Each item is rated on a 4-point Likert scale ranging from 0 (never) to 3 (almost always), yielding a total score ranging from 0 to 24. Higher scores indicate greater impulsivity. Changes in total BIS-Brief scores will be evaluated from baseline (V1) to post-intervention (V5) and from baseline (V1) to the 4-week follow-up (V6). |
| Secondary | Change in Depressive Symptom Severity as Assessed by the Children's Depression Rating Scale-Revised (CDRS-R) | Baseline (V1, Week 1), Post-intervention (V5, Weeks 4-5), and 4-week Follow-up (V6, Weeks 8-9) | The CDRS-R is a 17-item clinician-rated scale to measure the severity of depression of children and adolescents. The scale evaluates emotional, cognitive, behavioral, and somatic symptoms associated with depression. Depression symptoms are rated on a 5-point scale from 1 to 5 for sleep, appetite, and tempo of speech items and a 7-point scale from 1 to 7 for remaining 14 items. Total scores range from 17 (normal) to 113 (severe depression), with higher scores indicating greater severity of depressive symptoms. Changes in total CDRS-R scores will be evaluated from baseline (V1) to post-intervention (V5) and from baseline (V1) to the 4-week follow-up (V6). |
| Secondary | Change in Anxiety Symptoms as Assessed by the Screen for Child Anxiety Related Emotional Disorders (SCARED) | Baseline (V1, Week 1), Post-intervention (V5, Weeks 4-5), and 4-week Follow-up (V6, Weeks 8-9) | The SCARED is a 41-item questionnaire designed to assess anxiety symptoms in children and adolescents across five domains: panic/somatic symptoms, generalized anxiety, separation anxiety, social anxiety, and school avoidance. Each item is rated on a 3-point Likert scale ranging from 0 (not true or hardly ever true) to 2 (very true or often true), yielding a total score ranging from 0 to 82. Higher scores indicate greater severity of anxiety symptoms. A total score of 25 or higher suggests the possible presence of an anxiety disorder, while a score of 30 or higher indicates increased likelihood of an anxiety disorder. Changes in total SCARED scores will be evaluated from baseline (V1) to post-intervention (V5) and from baseline (V1) to the 4-week follow-up (V6). |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07910110
GET https://conductscience.org/api/trials/v1/NCT07910110/registered